- Sem Dados
Português
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
In this interview, Dr. Antonio Castelo, EPIC Biomedical and Laser Technology Manager, had a conversation with Aldas Juronis, CEO of EKSPLA, a Lithuanian innovative solid-state and fiber laser manufacturer.What is the background of your appointment as the CEO of EKSPLA?In 1994, I graduated from Kaonas University of Technology in Lithuania with a Bachelor's degree in Radio Electronic Engineering. At...
Recently, Dong Yibo, from the Photonic Chip Research Institute of Shanghai University of Technology, published his research findings titled "Nanoprinted Diffractive Layer Integrated Vertical Cavity Surface Emitting Vortex Lasers with Scalable Topological Charge" as the first author in the internationally renowned journal Nano Letters.This achievement was jointly completed by the team of academicia...
The widespread application in the fields of optical communication, computing, and sensing continues to drive the growing demand for high-performance integrated photonic components. Recently, Ali Najjar Amiri of Kochi University in Türkiye and other scholars proposed a highly scalable and highly flexible deep photonic network platform, which is used to realize optical systems on chip with arbi...
Recently, the reporter learned from Changguang Satellite Technology Co., Ltd. (hereinafter referred to as "Changguang Satellite") that the company used a self-developed vehicle mounted laser communication ground station to conduct satellite ground laser high-speed image transmission experiments with the onboard laser communication terminal of the "Jilin No.1" constellation MF02A04 satellite and ac...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...